TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28766264

Group type: EXPERIMENTAL
Intervention: Acetaminophen (20 mg/kg lean body mass)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 25671224

Group type: EXPERIMENTAL
Intervention: Moderation Only
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Abstinence Only
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Moderation to Abstinence
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Abstinence to Moderation
Number of subjects: 305
Study: 24820263

Group type: EXPERIMENTAL
Intervention: Cued attention with reward-prospect
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cued attention without reward-prospect
Number of subjects: 0
Study: 22716976

Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 288

Group type: COMPARATOR
Intervention: Ritonavir-boosted lopinavir
Number of subjects: 288
Study: 20619242

Group type: EXPERIMENTAL
Intervention: Losartan (angiotensin II receptor blocker)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 300
Study: 17364552

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg daily for up to 5 years
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Anastrozole 1 mg daily for up to 5 years
Number of subjects: 4000
Study: 16376249

Group type: EXPERIMENTAL
Intervention: Wound compression (inflatable cuff placed over the wound)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control (wound drainage)
Number of subjects: 105
Study: 12554545

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive therapy self-help program (n = 144)
Number of subjects: 144

Group type: COMPARATOR
Intervention: No-access control group (n = 155)
Number of subjects: 144
Study: 9522144

Group type: EXPERIMENTAL
Intervention: Tramadol 0.6 mg kg‐1
Number of subjects: 36

Group type: COMPARATOR
Intervention: Pethidine 0.6 mg kg‐1
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 8138636

Group type: EXPERIMENTAL
Intervention: Pure lavender oil
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Synthetic lavender oil
Number of subjects: 635

Group type: COMPARATOR
Intervention: Inert substance
Number of subjects: 635
Study: 2724233

Group type: EXPERIMENTAL
Intervention: Antenatal steroid administration
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Male infants
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Female infants
Number of subjects: 183
Study: 29969938

Group type: EXPERIMENTAL
Intervention: 12-week group-based cognitive remediation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 27
Study: 27246567

Group type: EXPERIMENTAL
Intervention: Varenicline (0, 1, 2 mg/d)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Varenicline (1 and 2 mg/d)
Number of subjects: 44

Group type: COMPARATOR
Intervention: High-dose alcohol (0.08 g/dl)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Nonalcohol control beverage
Number of subjects: 44
Study: 26420181

Group type: EXPERIMENTAL
Intervention: HMB/Arg/Gln supplementation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 23
Study: 24016495

Group type: EXPERIMENTAL
Intervention: Routine early eptifibatide
Number of subjects: 9406

Group type: COMPARATOR
Intervention: Delayed provisional use of eptifibatide
Number of subjects: 9406
Study: 19852709

Group type: EXPERIMENTAL
Intervention: 1 year of coaching to adopt health-enhancing physical activity (moderately intensive, 30 min/day, > 4 days/week)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 228
Study: 18840370

Group type: EXPERIMENTAL
Intervention: Capsule formulation of meclofenoxate hydrochloride 200 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Tablet formulation of meclofenoxate hydrochloride 200 mg
Number of subjects: 24
Study: 17054457

Group type: EXPERIMENTAL
Intervention: Recombinant GH for 6 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 16
Study: 12818406

Group type: EXPERIMENTAL
Intervention: 15 ml of linseed oil (rich in ALA) per day (n=50)
Number of subjects: 76

Group type: COMPARATOR
Intervention: 15 ml of safflower oil (rich in LA) per day (n=26)
Number of subjects: 76
Study: 11933306

Group type: EXPERIMENTAL
Intervention: Radiant heat therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study: 8775403

Group type: EXPERIMENTAL
Intervention: Synthetic ANF (0.01 microgram.kg.min, Anaritide, Wyeth Laboratories)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Metoclopramide (Met)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: ANF
Number of subjects: 6
Study: 1538208

Group type: EXPERIMENTAL
Intervention: brief pulse right unilateral ECT
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: brief pulse left unilateral ECT
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: brief pulse bilateral ECT
Number of subjects: 33
Study: 6240599

Group type: EXPERIMENTAL
Intervention: IK‐6‐Inhaletten (0.1 mg Fenoterol + 0.04 mg Ipratropiumbromide)
Number of subjects: 39

Group type: COMPARATOR
Intervention: SCH 1000‐Inhaletten (0.2 mg Ipratropiumbromide)
Number of subjects: 39
Study: 29629828

Group type: EXPERIMENTAL
Intervention: Telephone-based cognitive-behavioral therapy (T-CBT)
Number of subjects: 39
Study: 29478494

Group type: EXPERIMENTAL
Intervention: Purified nonreactive varieties of oats (15-40g)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo (gluten-free food)
Number of subjects: 177
Study: 27084301

Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behavioral Therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Internet-based Compassionate Mind Training (CMT)
Number of subjects: 0
Study: 20626584

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (2×10(8) CFU/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22331396

Group type: EXPERIMENTAL
Intervention: Nefopam (two different concentrations)
Number of subjects: 8
Study: 21154024

Group type: EXPERIMENTAL
Intervention: PMT group (intervention)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Non-PMT group (attention control)
Number of subjects: 166
Study: 17573446

Group type: EXPERIMENTAL
Intervention: Roflumilast 500 microg once daily for 4 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 15670372

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil-releasing microspheres (130 mg) with early radiotherapy (59.4 Gy)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Early radiotherapy alone (59.4 Gy)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil-releasing microspheres (130 mg) with early radiotherapy (59.4 Gy) in patients with complete resection
Number of subjects: 95

Group type: COMPARATOR
Intervention: Early radiotherapy alone (59.4 Gy) in patients with complete resection
Number of subjects: 95
Study: 12191977

Group type: EXPERIMENTAL
Intervention: Warfarin (target INR of 1.4 to 1.9)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 107
Study: 9807978

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study: 7612086

Group type: EXPERIMENTAL
Intervention: Infant Crib Air (ICA) apparatus
Number of subjects: 21
Study: 2238574

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 30
Study: 190971

Group type: EXPERIMENTAL
Intervention: Long-term hospitalization
Number of subjects: 141

Group type: COMPARATOR
Intervention: Short-term hospitalization
Number of subjects: 141
Study: 31691810

Group type: EXPERIMENTAL
Intervention: TJ-14
Number of subjects: 22
Study: 29649425

Group type: EXPERIMENTAL
Intervention: 60 g freeze‐dried polyphenol‐rich whole grape powder (GP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 4 weeks of daily GP consumption
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 20
Study: 28103829

Group type: EXPERIMENTAL
Intervention: Intravenous hydration with three litres of Hartmann's solution between midnight and 8 am before kidney donation
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no intravenous hydration)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Intravenous hydration
Number of subjects: 86
Study: 26122235

Group type: EXPERIMENTAL
Intervention: Antiviral therapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no antiviral therapy)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Sustained virus response to antiviral therapy
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: No response to antiviral therapy
Number of subjects: 54
Study: 23614999

Group type: EXPERIMENTAL
Intervention: BMS-663068 monotherapy
Number of subjects: 0
Study: 21923713

Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy (pantoprazole 40 mg + amoxicillin 1000 mg twice a day for 5 days, then pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg twice a day for 5 days)
Number of subjects: 409

Group type: COMPARATOR
Intervention: 14-day PPI-based triple therapy (pantoprazole 40 mg + amoxicillin 1000 mg + clarithromycin 500 mg twice a day for 14 days)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 409
Study: 18312035

Group type: EXPERIMENTAL
Intervention: Active tDCS (anodal stimulation of left and right DLPFC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 24
Study: 16400951

Group type: EXPERIMENTAL
Intervention: Qingkailing soft capsules (1.6 g, 4 times a day)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Shuanghuanglian kou fu liquid (control)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Qingkailing soft capsules
Number of subjects: 129
Study: 11817760

Group type: EXPERIMENTAL
Intervention: 10 mg of diazepam
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9785271

Group type: EXPERIMENTAL
Intervention: Total sleep time of 0 min (0 h TIB)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Total sleep time of 113 min (2 h TIB)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Total sleep time of 218 min (4 h TIB)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Total sleep time of 427 min (8 h TIB)
Number of subjects: 8
Study: 7881956

Group type: EXPERIMENTAL
Intervention: Colour Doppler ultrasonography assessment before and after operation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Clinical examination only (Control group)
Number of subjects: 38
Study: 2198177

Group type: EXPERIMENTAL
Intervention: Early GMH (evident on cranial ultrasonogram before the 12th postnatal hour)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early GMH
Number of subjects: 0
Study: 329975

Group type: EXPERIMENTAL
Intervention: CAF (cyclophosphamide, Adriamycin, 5-fluorouracil)
Number of subjects: 113

Group type: COMPARATOR
Intervention: CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone)
Number of subjects: 113
Study: 31855680

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (1.5 mg estradiol and 2.5 mg nomegestrolacetate)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (COC)
Number of subjects: 69
Study: 30872105

Group type: EXPERIMENTAL
Intervention: High meat group (minimum of 2 servings/week of red or processed meat)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Low meat group (not more than 1 serving per month of red or processed meat)
Number of subjects: 214
Study: 28618424

Group type: EXPERIMENTAL
Intervention: Preventive sealing
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Therapeutic sealing
Number of subjects: 61
Study: 26592847

Group type: EXPERIMENTAL
Intervention: Curcumin complexed with phosphatidylserine in phytosome form
Number of subjects: 44

Group type: COMPARATOR
Intervention: Pure phosphatidylserine
Number of subjects: 44
Study: 23989087

Group type: EXPERIMENTAL
Intervention: MIXED hemodiafiltration at Qb 250 ml/min
Number of subjects: 38

Group type: COMPARATOR
Intervention: PRE hemodiafiltration at Qb 250 ml/min
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: MIXED hemodiafiltration at Qb 300 ml/min
Number of subjects: 38

Group type: COMPARATOR
Intervention: PRE hemodiafiltration at Qb 300 ml/min
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: MIXED hemodiafiltration
Number of subjects: 38
Study: 21473660

Group type: EXPERIMENTAL
Intervention: Psychological family-based intervention (2 sessions by a health psychologist, plus a 15-minute follow-up call)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Psychological family-based intervention (specifically for those with A1C>9.5%)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Psychological family-based intervention
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (usual diabetes care)
Number of subjects: 121
Study: 19419350

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HS) 4 ml/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hydroxyethyl starch (HES) 4 ml/kg
Number of subjects: 50
Study: 16765146

Group type: EXPERIMENTAL
Intervention: Benazepril or Imidapril
Number of subjects: 509

Group type: COMPARATOR
Intervention: Control group (CC genotype)
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: A6547G polymorphism (AA, AG, GG genotypes)
Number of subjects: 509
Study: 15037404

Group type: EXPERIMENTAL
Intervention: Blastocyst-stage embryo transfer
Number of subjects: 54

Group type: COMPARATOR
Intervention: Day 2-3 embryo transfer
Number of subjects: 54
Study: 11688080

Group type: EXPERIMENTAL
Intervention: Dietary supplement in the form of a fortified powder fruit drink, consumed 25 grams per school day for six months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group), details not specified.
Number of subjects: 0
Study: 9264076

Group type: EXPERIMENTAL
Intervention: Alcohol (0.25, 0.5, or 1.0 g/kg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Marijuana (4.8 or 16 puffs of 3.55% THC)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 5
Study: 7888296

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 800 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine hydrochloride 300 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3250317

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg o.d.)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Metoprolol CR (100 mg o.d.)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Atenolol and Metoprolol CR
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Metoprolol CR
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 74
Study: 29931665

Group type: EXPERIMENTAL
Intervention: US-guided IBPB (U)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: PNS-confirmation IBPB (N)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: US-guided, PNS-confirmed IBPB (dual guidance; NU)
Number of subjects: 108

Group type: COMPARATOR
Intervention: All techniques (U, N, NU)
Number of subjects: 108
Study: 26501496

Group type: EXPERIMENTAL
Intervention: Challenging Horizons Program‐after school version (CHP‐AS)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Challenging Horizons Program‐mentoring version (CHP‐M)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Community care (CC)
Number of subjects: 326
Study: 25687836

Group type: EXPERIMENTAL
Intervention: Acticoat™
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Acticoat™ with Mepitel™
Number of subjects: 96

Group type: COMPARATOR
Intervention: Mepilex Ag™
Number of subjects: 96
Study: 23564211

Group type: EXPERIMENTAL
Intervention: Cetirizine 15 mg + Verapamil 120 mg (P-gp blocker)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Cetirizine 15 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: COMPARATOR
Intervention: Verapamil 120 mg
Number of subjects: 13
Study: 20224056

Group type: EXPERIMENTAL
Intervention: Standard dose alteplase (0.90 ± 0.02 mg/kg)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Lower dose alteplase (0.72 ± 0.07 mg/kg)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Standard dose alteplase (0.90 ± 0.02 mg/kg) in patients ≥ 70 years old
Number of subjects: 241

Group type: COMPARATOR
Intervention: Lower dose alteplase (0.72 ± 0.07 mg/kg) in patients ≥ 70 years old
Number of subjects: 241
Study: 18359865

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (400 mg to 1,200 mg) plus temozolomide (150-200 mg/m² per day on days 4-8)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (1,000 mg) plus temozolomide (150-200 mg/m² per day on days 4-8)
Number of subjects: 65
Study: 15076235

Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy (HAART)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 52
Study: 11559726

Group type: EXPERIMENTAL
Intervention: Comprehensive palliative care
Number of subjects: 434

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 434
Study: 9777766

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel plus mid-potency corticosteroid cream
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel plus high-potency corticosteroid cream
Number of subjects: 300

Group type: COMPARATOR
Intervention: Tazarotene 0.1% gel plus placebo cream
Number of subjects: 300
Study: 7835452

Group type: EXPERIMENTAL
Intervention: Diclofenac and gentamicin combination
Number of subjects: 80

Group type: COMPARATOR
Intervention: Betamethasone and neomycin combination
Number of subjects: 80
Study: 3035303

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3H‐clonidine and 3H‐imipramine binding
Number of subjects: 0
Study: 30904939

Group type: EXPERIMENTAL
Intervention: Metformin (up to 1 g twice daily)
Number of subjects: 27
Study: 29693650

Group type: EXPERIMENTAL
Intervention: Phenylbutyrate (NaPB; 7.15 g•m‐2BSA•day‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benzoate (NaBz; 5.5 g•m‐2BSA•day‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy (MIX arm; 3.575 g NaPB and 2.75 g NaBz•m‐2BSA•day‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy (MIX arm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenylbutyrate (NaPB)
Number of subjects: 0
Study: 27620995

Group type: EXPERIMENTAL
Intervention: Oral simvastatin 40 mg once daily for 3-7 days before surgery
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Oral simvastatin 40 mg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Oral simvastatin
Number of subjects: 144
Study: 25080284

Group type: EXPERIMENTAL
Intervention: Pedunculopontine nucleus area stimulation (off stimulation)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pedunculopontine nucleus area stimulation
Number of subjects: 6

Group type: COMPARATOR
Intervention: Levodopa intake
Number of subjects: 6

Group type: COMPARATOR
Intervention: Subthalamic nucleus stimulation
Number of subjects: 6

Group type: COMPARATOR
Intervention: Combination of levodopa intake and subthalamic nucleus stimulation
Number of subjects: 6
Study: 22574592

Group type: EXPERIMENTAL
Intervention: Biqi Capsule (BQC)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: BQC combined with MTX
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control (BQC or MTX alone)
Number of subjects: 138
Study: 19604584

Group type: EXPERIMENTAL
Intervention: Integrated cognitive behaviour therapy (CBT) treatment program, 10 sessions over 20 weeks.
Number of subjects: 60
Study: 17284737

Group type: EXPERIMENTAL
Intervention: High-fat diet (500 additional kcal)
Number of subjects: 52

Group type: COMPARATOR
Intervention: High-carbohydrate diet (500 additional kcal)
Number of subjects: 52

Group type: COMPARATOR
Intervention: High-protein diet (500 additional kcal)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard diet (20% protein, 30% fat, 50% carbohydrate)
Number of subjects: 52
Study: 15857738

Group type: EXPERIMENTAL
Intervention: Strontium-89
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Chemotherapy (FEM=5-FU, epirubicin, and mitomycin C)
Number of subjects: 35
Study: 11586809

Group type: EXPERIMENTAL
Intervention: Lipid-lowering treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 9392310

Group type: EXPERIMENTAL
Intervention: GST monitoring reported daily to the ward (reporting group)
Number of subjects: 49
Study: 7709992

Group type: EXPERIMENTAL
Intervention: Budesonide delivered via Turbuhaler
Number of subjects: 102

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) with volumatic spacer
Number of subjects: 102
Study: 3109602

Group type: EXPERIMENTAL
Intervention: 20% glucose solution with 6 g salt
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Boiled macaroni with 6 g salt
Number of subjects: 8

Group type: COMPARATOR
Intervention: 20% glucose solution without salt
Number of subjects: 8

Group type: COMPARATOR
Intervention: Boiled macaroni without salt
Number of subjects: 8
Study: 31506074

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) once daily for 20 minutes, electrical current increased up to 70 mA until contraction detected.
Number of subjects: 21
Study: 28414617

Group type: EXPERIMENTAL
Intervention: Targeted narrative intervention
Number of subjects: 316

Group type: COMPARATOR
Intervention: Control narrative (not explicitly mentioned)
Number of subjects: 316
Study: 26686043

Group type: EXPERIMENTAL
Intervention: Eltrombopag (50 mg to 300 mg daily)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 98